ZIKA-001: Safety and Immunogenicity of an Engineered DNA Vaccine against Zika virus infection

BACKGROUND: While Zika virus (ZIKV) infection is typically self-limited, congenital birth defects and Guillain-Barré syndrome are well-described. There are no approved ZIKV vaccines. METHODS: ZIKA-001, a phase I, open label, clinical trial evaluated the safety and immunogenicity of synthetic, consen...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:N Engl J Med
Huvudupphovsmän: Tebas, Pablo, Roberts, Christine C., Muthumani, Kar, Reuschel, Emma L., Kudchodkar, Sagar B., Zaidi, Faraz I., White, Scott, Khan, Amir S., Racine, Trina, Choi, Hyeree, Boyer, Jean, Park, Young K, Trottier, Sylvie, Remigio, Celine, Krieger, Diane, Spruill, Susan E., Kobinger, Gary P., Weiner, David B., Maslow, Joel N.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2021
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6824915/
https://ncbi.nlm.nih.gov/pubmed/34525286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1708120
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk